Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy-Reference-Cited by-同舟云学术

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Published:2013 Issue:5 Volume:15 Page:R137
ISSN:1478-6354
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Baraf Herbert SB,Becker Michael A,Gutierrez-Urena Sergio R,Treadwell Edward L,Vazquez-Mellado Janitzia,Rehrig Claudia D,Ottery Faith D,Sundy John S,Yood Robert A

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference27 articles.

1. Quality of Life and Disability in Patients with Treatment-Failure Gout

2. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study

3. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey

4. Concomitant septic and gouty arthritis--an analysis of 30 cases

5. Severe tophaceous gout

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction of an uricase/catalase/curcumin-co-loaded drug delivery system and its effect on hyper-uric acid-induced kidney injury;Smart Materials in Medicine;2024-09

2. Microneedle transdermal drug delivery as a candidate for the treatment of gouty arthritis: Material structure, design strategies and prospects;Acta Biomaterialia;2024-09

3. Uric acid in health and disease: From physiological functions to pathogenic mechanisms;Pharmacology & Therapeutics;2024-04

4. Moving urate-lowering therapy in gout beyond guideline recommendations;Seminars in Arthritis and Rheumatism;2024-04

5. Polymer–drug conjugates as nano-sized multi-targeting systems for the treatment of Alzheimer's disease;RSC Pharmaceutics;2024